Allergan (AGN) Stock Price, News & Analysis

Company Overview

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: $191.64 to $193.38
• 50-Day Range: $184.04 to $193.89
• 52-Week Range: $114.27 to $202.21
• Volume: 12.44 million shs
• Average Volume: 4.01 million shs
• Market Capitalization: $63.50 billion
• P/E Ratio: N/A
• Dividend Yield: 1.53%
• Price Target: N/A
• Consensus Rating: N/A

AGN Stock Analysis - Frequently Asked Questions

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) posted its quarterly earnings results on Monday, February, 10th. The company reported $5.22 earnings per share for the quarter, beating analysts' consensus estimates of $4.57 by $0.65. The firm's quarterly revenue was up 6.6% compared to the same quarter last year.

What other stocks do shareholders of Allergan own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allergan investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU) and Aegean Marine Petroleum Network (ANW).

Company Calendar

• Last Earnings: 2/10/2020
• Today: 12/21/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:AGN
• Previous Symbol: NYSE:ACT
• CUSIP: 01849010
• CIK: 1578845
• Web: www.allergan.com
• Phone: 862-261-7000
• Fax: N/A
• Employees: 17,400
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $17.64
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 11.56
• P/E Growth: 1.63
• Net Income: $-5,271,000,000.00
• Net Margins: -15.44%
• Pretax Margin: N/A
• Return on Equity: 8.46%
• Return on Assets: 5.31%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 1.01
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $16.09 billion
• Price / Sales: 3.95
• Cash Flow: $36.70 per share
• Price / Cash Flow: 5.26
• Book Value: $177.28 per share
• Price / Book: 1.09

Miscellaneous

• Outstanding Shares: 329,002,000
• Free Float: N/A
• Market Cap: $63.50 billion
• Optionable: Optionable
• Beta: 1.20